Qian Shang

Title: Qian Shang: Innovator in Pharmaceutical Research

Introduction

Qian Shang is a notable inventor based in Tianjin, China. He has made significant contributions to the field of pharmaceutical research, particularly in the development of innovative treatments for metabolic disorders.

Latest Patents

Qian Shang holds two patents that showcase his expertise and innovative spirit. The first patent is titled "Glucagon-derived peptide and use thereof." This invention provides a polypeptide derivative that exhibits a dual agonistic effect on GC/GLP-1 receptors. This synergistic effect enhances energy metabolism, effectively reducing blood glucose levels while also promoting weight loss and improving body fat levels. The efficacy of this invention surpasses that of a single GLP-1 receptor agonist. The second patent is for a "Carboxylic acid URAT1 inhibitor containing diarylmethane structure, preparation method and use thereof." This invention addresses the pharmaceutical treatment of hyperuricemia and gout. It involves a URAT1 inhibitor that contains a diarylmethane structure, along with its preparation method and pharmaceutical composition for treating these conditions.

Career Highlights

Qian Shang is affiliated with the Tianjin Institute of Pharmaceutical Research Co., Ltd. His work at this institute has been pivotal in advancing pharmaceutical innovations. His research focuses on developing effective treatments that address critical health issues.

Collaborations

Qian Shang has collaborated with notable colleagues, including Wei Liu and Yuquan Li. These collaborations have fostered a productive research environment, leading to significant advancements in their respective fields.

Conclusion

Qian Shang's contributions to pharmaceutical research through his innovative patents highlight his role as a leading inventor in the industry. His work continues to impact the treatment of metabolic disorders, showcasing the importance of innovation in healthcare.